Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | USP1 | O94782 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | JAK1 | P23458 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 6/20 | 0.39 |
| ▸ | TBK1 | Q9UHD2 | 3/20 | 0.39 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.39 |
| ▸ | NAMPT | P43490 | 3/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.38 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4497501 | 0.93 | KDM4E (0.45) | PKMBACE1TBK1BACE2NAMPT | |
| SCHEMBL4496248 | 0.82 | CSNK1E (0.43) | PKMCSNK1E | |
| Hydrochloric Acid SCHEMBL4496242 | 0.81 | CSNK1E (0.42) | PKMCSNK1E | |
| SCHEMBL4488299 | 0.78 | USP1 (0.45) | USP1NAMPTBCHE | |
| SCHEMBL28615089 | 0.77 | PKM (0.45) | PKMJAK2JAK1 | |
| SCHEMBL12687340 | 0.76 | NAMPT (0.47) | PKMNAMPT | |
| SCHEMBL17092679 | 0.75 | HTR2B (0.48) | CHEK2 | |
| SCHEMBL4496634 | 0.75 | MAPT (0.47) | PKMBACE1TBK1CHEK2 | |
| Hydrochloric Acid SCHEMBL4496250 | 0.74 | ALDH1A1 (0.49) | CSNK1E | |
| SCHEMBL6791011 | 0.72 | LCK (0.56) | PKMBCHECSNK1E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7524841-B2 | 4,4-disubstituted piperidine derivatives having CCR3 antagonism | TEIJIN LIMITED (JP) | 2009-04-28 | — | — | US | disclosed |
| US-20070037851-A1 | Inhibits binding of CCR3 ligands such as eotaxins to their target cells; inhibits physiological effects of binding; therapeutic and prophylactic agents for asthma, rhinitis, dermatitis, urticaria, conjunctivitis, inflammatory bowel; tissue infiltration of eosinophils, basophils, activated T cells | TEIJIN LIMITED, A JAPANESE BODY CORPORATE (JP) | 2007-02-15 | — | — | US | disclosed |
| EP-1505067-A1 | 4,4-DISUBSTITUTED PIPERIDINE DERIVATIVES HAVING CCR3 ANTAGONISM | TEIJIN LIMITED (JP) | 2005-02-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037851-A1 | Inhibits binding of CCR3 ligands such as eotaxins to their target cells; inhibits physiological effects of binding; therapeutic and prophylactic agents for asthma, rhinitis, dermatitis, urticaria, conjunctivitis, inflammatory bowel; tissue infiltration of eosinophils, basophils, activated T cells | CCR3, CCR1, CCR4 | PKM 4690/4885USP1 979/4885JAK2 510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.